- Home
- HBANZ vs A Comparison
HBANZ vs A Comparison
Compare HBANZ & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HBANZ
Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/1000th Interest in a Share of 5.50% Series L Non-Cumulative Perpetual Preferred Stock
Current Price
Company Overview
Basic Information| Metric | HBANZ | A |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4B | 39.8B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | HBANZ | A |
|---|---|---|
| Price | $21.41 | $121.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $161.06 |
| AVG Volume (30 Days) | 58.9K | ★ 2.3M |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $4,472,000,000.00 |
| Revenue This Year | N/A | $8.42 |
| Revenue Next Year | N/A | $6.12 |
| P/E Ratio | ★ N/A | $26.01 |
| Revenue Growth | N/A | ★ 6.43 |
| 52 Week Low | $21.17 | $96.43 |
| 52 Week High | $22.23 | $160.27 |
Technical Indicators
Market Signals| Indicator | HBANZ | A |
|---|---|---|
| Relative Strength Index (RSI) | 53.85 | 37.12 |
| Support Level | N/A | $109.69 |
| Resistance Level | $21.83 | $123.79 |
| Average True Range (ATR) | 0.25 | 3.70 |
| MACD | -0.06 | -0.12 |
| Stochastic Oscillator | 21.87 | 45.49 |
Price Performance
Historical ComparisonAbout A Agilent Technologies Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.